Explore more publications!
Healthy Living South Dakota
Got News to Share?

Healthy Living South Dakota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 11, 2025

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
September 11, 2025

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Indeterminate GlobeNewswire
A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry
September 11, 2025

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

Indeterminate GlobeNewswire
First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
September 11, 2025

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients

Indeterminate GlobeNewswire
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
September 11, 2025

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Indeterminate GlobeNewswire
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
September 11, 2025

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

Indeterminate GlobeNewswire
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
September 11, 2025

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

Indeterminate GlobeNewswire
Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique
September 11, 2025

Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique

Indeterminate GlobeNewswire
US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren
September 11, 2025

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren

Indeterminate GlobeNewswire
US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker
September 11, 2025

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker

Indeterminate GlobeNewswire
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
September 11, 2025

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

Indeterminate GlobeNewswire
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
September 11, 2025

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Indeterminate GlobeNewswire
Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire
September 11, 2025

Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire

Indeterminate GlobeNewswire
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
September 11, 2025

Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology

Indeterminate GlobeNewswire
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
September 11, 2025

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions